Dark Forest Capital Management LP Takes Position in Certara, Inc. (NASDAQ:CERT)

Dark Forest Capital Management LP acquired a new stake in Certara, Inc. (NASDAQ:CERT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 76,776 shares of the company's stock, valued at approximately $818,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Jane Street Group LLC increased its holdings in shares of Certara by 2.6% in the 3rd quarter. Jane Street Group LLC now owns 147,393 shares of the company's stock valued at $1,726,000 after acquiring an additional 3,732 shares during the last quarter. Barclays PLC increased its stake in Certara by 198.3% during the third quarter. Barclays PLC now owns 70,525 shares of the company's stock valued at $825,000 after purchasing an additional 46,880 shares during the last quarter. 272 Capital LP bought a new stake in Certara during the third quarter valued at $586,000. GAMMA Investing LLC raised its holdings in shares of Certara by 442.2% during the fourth quarter. GAMMA Investing LLC now owns 8,421 shares of the company's stock worth $90,000 after purchasing an additional 6,868 shares during the period. Finally, Kopion Asset Management LLC lifted its position in shares of Certara by 46.0% in the 4th quarter. Kopion Asset Management LLC now owns 555,643 shares of the company's stock worth $5,918,000 after buying an additional 175,005 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company's stock.

Analysts Set New Price Targets

CERT has been the subject of a number of recent research reports. KeyCorp boosted their price objective on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, April 16th. Robert W. Baird increased their price target on Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. Barclays reduced their price objective on Certara from $13.00 to $11.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Stephens reaffirmed an "overweight" rating and issued a $17.00 target price on shares of Certara in a research report on Thursday, February 27th. Finally, William Blair reissued a "market perform" rating on shares of Certara in a report on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $15.17.

Certara Stock Performance

CERT stock traded down $0.44 during trading on Monday, reaching $13.73. 2,010,775 shares of the company's stock were exchanged, compared to its average volume of 1,222,873. Certara, Inc. has a 1-year low of $8.64 and a 1-year high of $17.94. The firm has a market cap of $2.22 billion, a PE ratio of -68.65, a P/E/G ratio of 9.29 and a beta of 1.64. The company's fifty day moving average price is $11.65 and its 200-day moving average price is $11.57. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.